India Pharma and Healthcare Sector Report 2026-2027

India's pharmaceutical and healthcare sector is globally recognised. India's reputation as the "pharmacy of the world" was established through its extensive production of generic medications and vaccines. For example, the Serum Institute of India, a vaccine manufacturer, played a pivotal role in developing COVID-19 vaccines. Meanwhile, Indian hospitals are accommodating a growing number of medical tourists due to their reputation for delivering high-quality, cost-effective healthcare. Indian patients are increasingly able to access modern healthcare, primarily due to higher participation in Ayushman Bharat, the government-sponsored public health insurance scheme. Despite these encouraging signs, India's pharmaceutical and healthcare sector faces daunting challenges. India's healthcare infrastructure remains limited due to decades of underfunding and the persistent migration of skilled medical professionals to higher-paying countries. The Indian healthcare system also relies on imported pharmaceutical raw materials, medical devices, and patented medicines owing to its limited domestic manufacturing capacity.

This report provides a complete and detailed analysis of the "Healthcare and pharma" sector for India. EMIS Insights presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

• Understand the key elements at play in the "Healthcare and pharma" sector in India
• Crystallise the forces both driving and restraining this sector in India
• Ascertain India’s position in the global sector
• Build a complete perspective on sector trade, investment and employment
• Understand the competitive landscape and who the major players are
• View M&A activity and major deals
• Gain an understanding of the regulatory environment for the sector in India.
• Build a clear picture of trends, output and consumption for specific sub-sectors